Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

By Dan Stanton

- Last updated on GMT

Capsugel says its Xcelodose Precision Powder Micro-Dosing System can shorten drug development time by up to six months. 

In-Pharmatechnologist.com spoke with Missy Lowery, Marketing Manager for the Americas at Capsugel, at this year’s Interphex in New York City about the company’s Fast track Solutions System and its Xcelodose proprietary technology.

“Speed to market is the most important”​ thing in the pharma market today, she told us.

“Capsugel’s proprietary technology provides an RSD of 1% for quantities as low as 100microgrammes directly into the capsule.”

She told us that Xcelodose was established in order for companies to put APIs directly in a capsule without going through the process of formulation first.

From concept to first clinical trial, Lowery said this technology has sped the whole process up by more than six months.

With “the accuracy of dosing, the continuation of the RSD,”​ she added, “there is nothing like it on the market right now.”

Related news

Show more

Related products

show more

Roquette Oral Dose Case Study

Roquette Oral Dose Case Study

Roquette Pharma Solutions | 06-Nov-2017 | Case Study

Download the case study and learn more on how Roquette’s taste masking technology KLEPTOSE® Linecaps (KL) allows the delivery of an efficient taste masking...

The Solid Dose, Latest News from Colorcon

The Solid Dose, Latest News from Colorcon

Colorcon Inc. | 06-Nov-2017 | Data Sheet

With a commitment to serve customers through product innovation and technical excellence, Colorcon's Solid Dose newsletter brings you the latest insight...

Related suppliers